Evidence map›Paper›PMID 39043935›Full record

ArticleScientific reports2024

Pharmacokinetics of anti-Mycobacterium avium-intracellulare disease drugs in silkworms.

Fumiya Watanabe, Yasuhiko Matsumoto, Takashi Sugita, Yuta Morishige, Satoshi Mitarai, Yoshihiko Hoshino, Kazuhiko Hanada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Establishment of anAntimicrobial agents and chemotherapy · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fumiya WatanabeDepartment of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, 204-8588, Japan. fwatanabe@my-pharm.ac.jp.
Yasuhiko MatsumotoDepartment of Microbiology, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, 204-8588, Japan.
Takashi SugitaDepartment of Microbiology, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, 204-8588, Japan.
Yuta MorishigeResearch Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo, Japan.
Satoshi MitaraiResearch Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo, Japan.
Yoshihiko HoshinoDepartment of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, 4-2-1 Aoba, Higashi-Murayama, Tokyo, Japan.
Kazuhiko HanadaDepartment of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, 204-8588, Japan.

Funding

Encouragement of Scientists JP24H02649Japan Agency for Medical Research and Development/Japan International Cooperation Agency (AMED) JP20fk0108064, JP20fk0108075, JP21fk0108093, JP21fk0108129, JP22jm0510004, JP22wm0225004, JP22wm0325003, JP22fk0108553,　JP 22fk0108558, JP23fk0108608, JP23fk0108673, JP23gm1610003, JP23gm1610007, JP23wm0125007, JP23wm0225022, and JP23wm0325054Japan Agency for Medical Research and Development/Japan International Cooperation Agency (AMED) JP23wm0325054 and JP22fk0108553h0001Japan Society for the Promotion of Science JP63KK0138-ANagai Memorial Research Scholarship N202704Scientific Research (C) JP20K07022Scientific Research (C) JP23K07665 and JP23K07958the Joint Research Program in Meiji Pharmaceutical University JRP22MPU
6 · The paper itself

Abstract

Pulmonary Mycobacterium avium-intracellulare complex (MAC) disease is a typical non-tuberculous mycobacterial infection. The incidence of pulmonary MAC is increasing worldwide. This study aimed to clarify the pharmacokinetic parameters of anti-pulmonary MAC disease drugs in silkworms. The pharmacokinetic parameters investigated included maximum concentration, area under the concentration-time curve, total clearance, and volume of distribution at steady-state. In addition, protein-binding rates, fat body transferability, and drug-drug interactions were examined. Antibiotic concentrations were measured using a validated high-performance liquid chromatography-mass spectrometry method. Among the antibiotics investigated, amikacin was not eliminated from silkworms during the 48-h observation period. In contrast, dose-proportional pharmacokinetics were observed in silkworms for all antibiotics tested, except for amikacin. Protein-binding rates in hemolymph for clarithromycin, azithromycin, rifampicin, ethambutol, and amikacin were 39.6 ± 3.0%, 39.5 ± 4.3%, 76.3 ± 3.2%, 20.9 ± 4.2%, and 73.1 ± 4.7%, respectively (mean ± standard deviation). The distribution of antibiotics in the fat bodies of silkworms was related to drug lipophilicity. No drug-drug interactions were observed in the silkworms. The pharmacokinetics of these drugs in silkworms differed significantly from those in humans. Therefore, while it is challenging to predict the pharmacokinetics of these drugs in humans based on silkworm data, the silkworm infection model has facilitated a comprehensive assessment of the relationship between antibiotic exposure and efficacy.

Indexed as

AmikacinAnti-Bacterial AgentsBombyxMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionAnimalsClarithromycinDrug InteractionsEthambutolHemolymphProtein BindingRifampinAmikacinAnti-Bacterial AgentsClarithromycinEthambutolRifampin

Identifiers

PMID39043935
PMCPMC11266716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.